|
1
|
Zhang HW, Wang F and Ding J: Updates on
the molecular genetics of congenital nephrotic syndrome. Zhonghua
Er Ke Za Zhi. 49:425–427. 2011.(In Chinese). PubMed/NCBI
|
|
2
|
Stahl RA, Hoxha E and Helmchen U:
Membranous glomerulonephritis: better therapy with autoantibody
monitoring? Dtsch Med Wochenschr. 136:1733–1737. 2011.(In German).
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruneau S and Dantal J: New insights into
the pathophysiology of idiopathic nephrotic syndrome. Clin Immunol.
133:13–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bomback AS and Radhakrishnan J: Treatment
of nephrotic syndrome with adrenocorticotropic hormone (ACTH).
Discov Med. 12:91–96. 2011.PubMed/NCBI
|
|
5
|
Saito T: Treatment and prognosis of
idiopathic membranous nephropathy in guidelines for nephrotic
syndrome. Nihon Jinzo Gakkai Shi. 53:708–712. 2011.(In Japanese).
PubMed/NCBI
|
|
6
|
Guess A, Agrawal S, Wei CC, Ransom RF,
Benndorf R and Smoyer WE: Dose- and time-dependent glucocorticoid
receptor signaling in podocytes. Am J Physiol Renal Physiol.
299:F845–F853. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang L, Li Q, Wang LJ and Li X: Level of
Th17 cell and CD4(+); CD25(+); Foxp3(+); regulatory T cell in
peripheral blood mononuclear cells of primary nephrotic syndrome in
children. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 26:783–786. 2010.(In
Chinese). PubMed/NCBI
|
|
8
|
Farid FA, Mohammed AA, Afifi HM and
Beltagi RS: Tissue factor pathway inhibitor in paediatric patients
with nephrotic syndrome. SAJCH. 5:107–111. 2011.PubMed/NCBI
|
|
9
|
Tan Y, Yang D, Fan J and Chen Y: Elevated
levels of immunoglobulin E may indicate steroid resistance or
relapse in adult primary nephrotic syndrome, especially in minimal
change nephrotic syndrome. J Int Med Res. 39:2307–2313. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Audard V, Pawlak A, Candelier M, Lang P
and Sahali D: Upregulation of nuclear factor-related kappa B
suggests a disorder of transcriptional regulation in minimal change
nephrotic syndrome. PLoS One. 7:e305232012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Caridi G, Trivelli A, SannaCherchi S,
Perfumo F and Ghiggeri GM: Familial forms of nephrotic syndrome.
Pediatr Nephrol. 25:241–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elie V, Fakhoury M, Deschênes G and
Jacqz-Aigrain E: Physiopathology of idiopathic nephrotic syndrome:
lessons from glucocorticoids and epigenetic perspectives. Pediatr
Nephrol. 27:1249–1256. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Segal PE and Choi MJ: Recent advances and
prognosis in idiopathic membranous nephropathy. Adv Chronic Kidney
Dis. 19:114–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shalaby SA, El Idrissy HM, Safar RA and
Hussein ST: Glucocorticoid receptors and the pattern of steroid
response in idiopathic nephrotic syndrome. Arab J Nephrol
Transplant. 5:13–17. 2012.PubMed/NCBI
|
|
15
|
Szilagyi K, Podracka L, Franke NE, Mojzis
J and Mirossay L: A new link between steroid resistance,
glucocorticoid receptor and nuclear factor kappa B p65 in
idiopathic nephrotic syndrome. Neuro Endocrinol Lett. 30:629–636.
2009.PubMed/NCBI
|
|
16
|
Chen P, Jiang T, Ouyang J and Cui Y:
Glucocorticoid receptor auto-upregulation and its relation with
glucocorticoid sensitivity in idiopathic nephrotic syndrome. Int
Urol Nephrol. 43:167–174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pace TW, Hu F and Miller AH:
Cytokine-effects on glucocorticoid receptor function: relevance to
glucocorticoid resistance and the pathophysiology and treatment of
major depression. Brain Behav Immun. 21:9–19. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang X, Wu H, Lakdawala VS, Hu F, Hanson
ND and Miller AH: Inhibition of Jun N-terminal kinase (JNK)
enhances glucocorticoid receptor-mediated function in mouse
hippocampal HT22 cells. Neuropsychopharmacology. 30:242–249. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang X, Wu H and Miller AH: Interleukin
1alpha (IL-1alpha) induced activation of p38 mitogen-activated
protein kinase inhibits glucocorticoid receptor function. Mol
Psychiatry. 9:65–75. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rogatsky I and Ivashkiv LB: Glucocorticoid
modulation of cytokine signaling. Tissue Antigens. 68:1–12. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Biola A, Lefebvre P, PerrinWolff M, Sturm
M, Bertoglio J and Pallardy M: Interleukin-2 inhibits
glucocorticoid receptor transcriptional activity through a
mechanism involving STAT5 (signal transducer and activator of
transcription 5) but not AP-1. Mol Endocrinol. 15:1062–1076. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kam JC, Szefler SJ, Surs W, Sher ER and
Leung DY: Combination IL-2 and IL-4 reduces glucocorticoid
receptor-binding affinity and T cell response to glucocorticoids. J
Immunol. 151:3460–3466. 1993.PubMed/NCBI
|
